v3.24.1.1.u2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 2,392 $ 1,215
Research and development – licenses acquired 0 4,230
General and administrative 1,316 984
Loss from operations (3,708) (6,429)
Other income (expense):    
Interest income 49 37
Financing costs – warrant liabilities 0 (332)
Loss on settlement of common stock warrant liabilities (574) 0
Change in fair value of warrant liabilities (116) (878)
Total other income (expense) (641) (1,173)
Net loss (4,349) (7,602)
Net loss attributable to non-controlling interests (9) (66)
Net loss attributable to common stockholders $ (4,340) $ (7,536)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (15.4) $ (101.57)
Weighted average number of common shares outstanding, basic and diluted (in shares) 562,031 74,198

Source